<p>ReposiTrak NYSE: TRAK 报告了基本持平的财政第三季度收入，同时强调了更强的盈利能力、持续的现金生成以及与食品可追溯性、人工智能和店内执行相关的新战略举措。</p>
<p>在公司 2026 财政第三季度的电话会议上，首席财务官约翰·梅里尔表示，收入为 590 万美元，与去年同期持平。他提到，去年同期由于在原 FDA 合规截止日期之前的可追溯性入驻活动增加，导致当时收入增长约 16%。在 FDA 延长 FSMA 204 合规截止日期后，最新季度未能再次出现这种加速入驻的情况。</p>
<p>尽管收入比较持平，但盈利能力有所改善。梅里尔表示，总运营费用同比下降 12%，从 410 万美元降至 360 万美元。营业收入从 180 万美元上升 24%，达到约 230 万美元。GAAP 净收入增加 1%，约为 200 万美元，而归属于普通股股东的净收入上升 4%，约为 200 万美元。</p>
<p>基本每股收益为 0.11 美元，稀释每股收益为 0.10 美元。</p>
<h2>经常性收入模型仍然是战略的核心</h2>
<p>梅里尔将本季度框架置于 ReposiTrak 向经常性软件即服务模型的长期转型中。他表示，自 2020 财政年度以来，公司已将超过 700 万美元的历史一次性收入流转化为经常性 SaaS 收入。在此期间，经常性收入从总收入的约 62% 增加到今天的 98% 以上。</p>
<p>他还表示，ReposiTrak 消除了约 200 万美元的 “高接触、低利润” 收入机会，这些机会不再与其长期战略相符。尽管这些决定在当时减少了短期收入机会，但梅里尔表示，它们为更高价值的经常性收入创造了空间，并帮助公司为利润扩张做好了准备。</p>
<p>自 2020 财政年度以来，年运营费用已从约 1900 万美元下降至约 1600 万美元，公司已消除了 640 万美元的银行债务，梅里尔表示。净利润率已从几年前的约 8% 扩大到 “今天超过 30%”，他表示这证明了 SaaS 模型的运营杠杆。</p>
<h2>年初至今收入和收益增加</h2>
<p>在 2026 财政年度的前九个月，ReposiTrak 报告收入为 1770 万美元，比去年同期的 1680 万美元增长 5%。总运营费用下降 4%，至 1170 万美元。营业收入从 460 万美元增加 28%，达到 600 万美元。</p>
<p>GAAP 净收入在九个月期间上升 6%，达到 550 万美元，归属于普通股股东的净收入增加 9%，达到 540 万美元。稀释每股收益从 0.26 美元上升 9%，达到 0.28 美元。</p>
<p>梅里尔指出，公司不再受益于显著的净运营亏损结转来抵消应税收入。在第三季度，税费较去年同期增加约 200%，约增加 30 万美元。公司本季度的有效税率约为 18%，梅里尔表示 ReposiTrak 继续预计未来的有效税率约为 20%。</p>
<p>ReposiTrak 在季度末现金约为 2640 万美元，没有银行债务。公司在 2026 财政年度的前九个月中产生了 600 万美元的运营现金。</p>
<h2>资本回报通过回购、赎回和分红持续进行</h2>
<p>梅里尔表示，ReposiTrak 在当前财政年度至今已通过普通股回购、优先股赎回和分红向股东返还了约 500 万美元。</p>
<p>在 2026 财政年度，公司以约 180 万美元的价格回购了 144,000 股普通股，平均价格约为每股 12.50 美元。自回购计划启动以来，ReposiTrak 已回购约 230 万股，花费约 1500 万美元，平均成本约为每股 6.60 美元。梅里尔表示，现有董事会授权下仍有 600 万美元可用。</p>
<p>他补充说，公司不持有库存股；回购的股票会立即注销。</p>
<p>ReposiTrak 在 2026 财政年度还赎回了 175,000 股优先股，约有 161,000 股优先股仍在流通中。2026 年 3 月 20 日，董事会宣布每股现金分红 0.02 美元，支付给截至 2026 年 3 月 31 日的股东。这标志着自 2022 年 9 月启动该计划以来，连续第三年实现 10% 的分红增长。</p>
<h2>可追溯性、专利和人工智能举措受到关注</h2>
<p>董事长兼首席执行官兰迪·菲尔兹表示，本季度在战略上非常重要，因为公司通过知识产权保护和新关系增加了差异化。他表示，ReposiTrak 的业务线正在汇聚成一个单一的客户应用平台，为公司及其客户提供运营和财务优势。</p>
<p>菲尔兹强调了公司的无接触可追溯性举措，他将其描述为一种基于人工智能的自学习自动化解决方案。他表示，ReposiTrak 在销售该解决方案之前等待相关专利申请的提交，但现在销售已经开始。</p>
<p>梅里尔表示，ReposiTrak 在本季度提交了两个额外的专利申请。其中一个与无接触可追溯性直接相关，另一个涵盖了在集成供应链环境中识别和自动纠正数据完整性问题的方法。他表示，公司现在拥有九项美国专利的组合。</p>
<p>Fields 表示，南部美国的一家领先的杂货零售商和一家领先的批发杂货合作社在过去 45 天内使用 ReposiTrak 的无接触追溯解决方案实现了全面的端到端追溯。他表示，这些客户可以在不接触产品或大量投资于手动流程的情况下，从供应商追踪产品到分销中心，再到零售店。</p>
<p>Fields 还表示，供应商数据的准确性仍然是一个主要的追溯问题。他说，公司收到的供应商数据的初始错误率至少为 50%，最高可达 70%，并补充说，问题通常是数据不正确而不是缺失数据。他表示，ReposiTrak 开发了一种基于人工智能的系统，以近实时识别和纠正此类错误。</p>
<h2>SPAR 合作旨在店内执行</h2>
<p>Fields 还讨论了 ReposiTrak 与 SPAR 集团的合作，表示这可以将公司的能力从识别供应链和零售问题扩展到帮助解决这些问题。他表示，ReposiTrak 可以识别诸如缺货、需要从货架上移除的产品或召回相关问题等问题，而 SPAR 可以提供团队来解决这些问题。</p>
<p>“零售中的瓶颈不是智能，而是人手，” Fields 说。“SPAR 提供人手。”</p>
<p>在回应 Maxim Group 分析师 Thomas Forte 的问题时，Fields 表示，投资者可能会在六到九个月内开始看到 SPAR 关系的财务影响。他表示，ReposiTrak 和 SPAR 已经向一家大型消费品和制药公司展示了这一概念，并将潜在机会描述为有意义，如果能够发展的话。</p>
<p>展望未来，Merrill 表示 ReposiTrak 的优先事项仍然是有序执行、可持续的经常性收入增长、盈利能力扩展、审慎的资本配置、资产负债表强度和长期股东价值创造。Fields 表示，公司在供应链业务中看到 “出色的扩展”，并在追溯工作中注意到加速的初始阶段，同时指出这两项服务在活动和收入确认之间存在滞后。</p>
<h2>关于 ReposiTrak NYSE: TRAK</h2>
<p>ReposiTrak 在纽约证券交易所以 TRAK 为交易符号，是一家提供基于云的供应链合规性和透明度解决方案的公司。该公司的平台使零售商、供应商和制造商能够在整个供应链中管理、共享和验证产品数据。通过其软件即服务（SaaS）产品，ReposiTrak 帮助组织确保遵守食品安全、可持续性、标签和质量保证的监管要求、行业标准和零售商特定指南。</p>
<p>ReposiTrak 产品的核心是其 DataHub，这是一个集中存储库，捕获关键的信息，如产品规格、认证、称重数据、温度记录和召回通知。</p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 ReposiTrak 吗？</h2>
<p>在考虑 ReposiTrak 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买...而 ReposiTrak 并不在名单上。</p>
<p>虽然 ReposiTrak 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TRAK

<p>ReposiTrak（纽约证券交易所代码：TRAK）报告第三季度收入持平，为 590 万美元，但运营收入增长 24%，达到 230 万美元，盈利能力有所改善。该公司正在向经常性 SaaS 模式转型，使经常性收入超过 98%。截至目前，收入增长 5%，达到 1770 万美元，净收入增长 6%，达到 550 万美元。ReposiTrak 向股东返还了 500 万美元，并宣布每股 0.02 美元的季度股息，增长 10%。这一季度在食品追溯和人工智能的战略举措上具有重要意义</p>

<p>ReposiTrak NYSE: TRAK reported essentially flat fiscal third-quarter revenue while highlighting stronger profitability, continued cash generation and new strategic initiatives tied to food traceability, artificial intelligence and in-store execution.</p>
<div class="lb-trans"><p>ReposiTrak NYSE: TRAK 报告了基本持平的财政第三季度收入，同时强调了更强的盈利能力、持续的现金生成以及与食品可追溯性、人工智能和店内执行相关的新战略举措。</p>
</div><p>On the company’s fiscal third-quarter 2026 conference call, Chief Financial Officer John Merrill said revenue was $5.9 million, unchanged from the prior-year quarter. He said the year-ago period benefited from elevated traceability onboarding activity ahead of the original FDA compliance deadlines, which contributed to approximately 16% revenue growth at that time. Following the FDA’s extension of the FSMA 204 compliance deadline, that level of accelerated onboarding did not recur in the latest quarter.</p>
<div class="lb-trans"><p>在公司 2026 财政第三季度的电话会议上，首席财务官约翰·梅里尔表示，收入为 590 万美元，与去年同期持平。他提到，去年同期由于在原 FDA 合规截止日期之前的可追溯性入驻活动增加，导致当时收入增长约 16%。在 FDA 延长 FSMA 204 合规截止日期后，最新季度未能再次出现这种加速入驻的情况。</p>
</div><p>Despite the revenue comparison, profitability improved. Merrill said total operating expenses declined 12% year over year to $3.6 million from $4.1 million. Income from operations rose 24% to approximately $2.3 million from $1.8 million. GAAP net income increased 1% to approximately $2 million, while net income attributable to common shareholders rose 4% to approximately $2 million.</p>
<div class="lb-trans"><p>尽管收入比较持平，但盈利能力有所改善。梅里尔表示，总运营费用同比下降 12%，从 410 万美元降至 360 万美元。营业收入从 180 万美元上升 24%，达到约 230 万美元。GAAP 净收入增加 1%，约为 200 万美元，而归属于普通股股东的净收入上升 4%，约为 200 万美元。</p>
</div><p>Basic earnings per share were $0.11, and diluted earnings per share were $0.10.</p>
<div class="lb-trans"><p>基本每股收益为 0.11 美元，稀释每股收益为 0.10 美元。</p>
</div><h2>Recurring revenue model remains central to strategy</h2>
<div class="lb-trans"><h2>经常性收入模型仍然是战略的核心</h2>
</div><p>Merrill framed the quarter within ReposiTrak’s longer-term transition toward a recurring software-as-a-service model. He said the company has converted more than $7 million of historical one-time revenue streams into recurring SaaS revenue since fiscal 2020. Over the same period, recurring revenue increased from about 62% of total revenue to more than 98% today.</p>
<div class="lb-trans"><p>梅里尔将本季度框架置于 ReposiTrak 向经常性软件即服务模型的长期转型中。他表示，自 2020 财政年度以来，公司已将超过 700 万美元的历史一次性收入流转化为经常性 SaaS 收入。在此期间，经常性收入从总收入的约 62% 增加到今天的 98% 以上。</p>
</div><p>He also said ReposiTrak eliminated approximately $2 million of “high-touch, low-margin” revenue opportunities that no longer aligned with its long-term strategy. While those decisions reduced near-term revenue opportunities at the time, Merrill said they created capacity for higher-value recurring revenue and helped position the company for margin expansion.</p>
<div class="lb-trans"><p>他还表示，ReposiTrak 消除了约 200 万美元的 “高接触、低利润” 收入机会，这些机会不再与其长期战略相符。尽管这些决定在当时减少了短期收入机会，但梅里尔表示，它们为更高价值的经常性收入创造了空间，并帮助公司为利润扩张做好了准备。</p>
</div><p>Since fiscal 2020, annual operating expenses have declined from approximately $19 million to roughly $16 million, and the company has eliminated $6.4 million of bank debt, Merrill said. Net margins have expanded from approximately 8% several years ago to “north of 30% today,” which he said demonstrates the operating leverage of the SaaS model.</p>
<div class="lb-trans"><p>自 2020 财政年度以来，年运营费用已从约 1900 万美元下降至约 1600 万美元，公司已消除了 640 万美元的银行债务，梅里尔表示。净利润率已从几年前的约 8% 扩大到 “今天超过 30%”，他表示这证明了 SaaS 模型的运营杠杆。</p>
</div><h2>Year-to-date revenue and earnings increased</h2>
<div class="lb-trans"><h2>年初至今收入和收益增加</h2>
</div><p>For the first nine months of fiscal 2026, ReposiTrak reported revenue of $17.7 million, up 5% from $16.8 million in the prior-year period. Total operating expenses declined 4% to $11.7 million. Income from operations increased 28% to $6 million from $4.6 million.</p>
<div class="lb-trans"><p>在 2026 财政年度的前九个月，ReposiTrak 报告收入为 1770 万美元，比去年同期的 1680 万美元增长 5%。总运营费用下降 4%，至 1170 万美元。营业收入从 460 万美元增加 28%，达到 600 万美元。</p>
</div><p>GAAP net income for the nine-month period rose 6% to $5.5 million, and net income attributable to common shareholders increased 9% to $5.4 million. Diluted earnings per share rose 9% to $0.28 from $0.26.</p>
<div class="lb-trans"><p>GAAP 净收入在九个月期间上升 6%，达到 550 万美元，归属于普通股股东的净收入增加 9%，达到 540 万美元。稀释每股收益从 0.26 美元上升 9%，达到 0.28 美元。</p>
</div><p>Merrill noted that the company no longer benefits from significant net operating loss carryforwards to offset taxable income. In the third quarter, tax expense increased approximately 200% from the prior-year period, representing roughly a $300,000 increase. The company’s effective tax rate was approximately 18% for the quarter, and Merrill said ReposiTrak continues to model an effective tax rate of about 20% going forward.</p>
<div class="lb-trans"><p>梅里尔指出，公司不再受益于显著的净运营亏损结转来抵消应税收入。在第三季度，税费较去年同期增加约 200%，约增加 30 万美元。公司本季度的有效税率约为 18%，梅里尔表示 ReposiTrak 继续预计未来的有效税率约为 20%。</p>
</div><p>ReposiTrak ended the quarter with approximately $26.4 million in cash and no bank debt. The company generated $6 million in cash from operations during the first nine months of fiscal 2026.</p>
<div class="lb-trans"><p>ReposiTrak 在季度末现金约为 2640 万美元，没有银行债务。公司在 2026 财政年度的前九个月中产生了 600 万美元的运营现金。</p>
</div><h2>Capital returns continue through buybacks, redemptions and dividends</h2>
<div class="lb-trans"><h2>资本回报通过回购、赎回和分红持续进行</h2>
</div><p>Merrill said ReposiTrak returned roughly $5 million to shareholders during the current fiscal year-to-date period through common share repurchases, preferred share redemptions and dividends.</p>
<div class="lb-trans"><p>梅里尔表示，ReposiTrak 在当前财政年度至今已通过普通股回购、优先股赎回和分红向股东返还了约 500 万美元。</p>
</div><p>During fiscal 2026, the company repurchased 144,000 common shares for approximately $1.8 million at an average price of about $12.50 per share. Since the inception of the buyback program, ReposiTrak has repurchased approximately 2.3 million shares for approximately $15 million at an average cost of roughly $6.60 per common share. Merrill said $6 million remains under the existing board authorization.</p>
<div class="lb-trans"><p>在 2026 财政年度，公司以约 180 万美元的价格回购了 144,000 股普通股，平均价格约为每股 12.50 美元。自回购计划启动以来，ReposiTrak 已回购约 230 万股，花费约 1500 万美元，平均成本约为每股 6.60 美元。梅里尔表示，现有董事会授权下仍有 600 万美元可用。</p>
</div><p>He added that the company does not hold treasury shares; repurchased shares are immediately retired.</p>
<div class="lb-trans"><p>他补充说，公司不持有库存股；回购的股票会立即注销。</p>
</div><p>ReposiTrak also redeemed 175,000 preferred shares during fiscal 2026, with approximately 161,000 preferred shares remaining outstanding. On March 20, 2026, the board declared a quarterly cash dividend of $0.02 per share payable to shareholders of record as of March 31, 2026. Merrill said this marked the third consecutive annual 10% dividend increase since the program was initiated in September 2022.</p>
<div class="lb-trans"><p>ReposiTrak 在 2026 财政年度还赎回了 175,000 股优先股，约有 161,000 股优先股仍在流通中。2026 年 3 月 20 日，董事会宣布每股现金分红 0.02 美元，支付给截至 2026 年 3 月 31 日的股东。这标志着自 2022 年 9 月启动该计划以来，连续第三年实现 10% 的分红增长。</p>
</div><h2>Traceability, patents and AI initiatives highlighted</h2>
<div class="lb-trans"><h2>可追溯性、专利和人工智能举措受到关注</h2>
</div><p>Chairman and Chief Executive Officer Randy Fields said the quarter was “strategically important” as the company added differentiation through intellectual property protection and a new relationship. He said ReposiTrak’s business lines are converging into a single platform of applications for customers, giving the company and its customers operational and financial advantages.</p>
<div class="lb-trans"><p>董事长兼首席执行官兰迪·菲尔兹表示，本季度在战略上非常重要，因为公司通过知识产权保护和新关系增加了差异化。他表示，ReposiTrak 的业务线正在汇聚成一个单一的客户应用平台，为公司及其客户提供运营和财务优势。</p>
</div><p>Fields emphasized the company’s Touchless Traceability initiative, which he described as an AI-powered, self-learning automated solution for traceability. He said ReposiTrak waited until related patent filings were made before selling the solution, but selling is now beginning.</p>
<div class="lb-trans"><p>菲尔兹强调了公司的无接触可追溯性举措，他将其描述为一种基于人工智能的自学习自动化解决方案。他表示，ReposiTrak 在销售该解决方案之前等待相关专利申请的提交，但现在销售已经开始。</p>
</div><p>Merrill said ReposiTrak filed two additional patent applications during the quarter. One relates directly to Touchless Traceability, and the other covers methods for identifying and automatically correcting data integrity issues in integrated supply chain environments. The company now maintains a portfolio of nine U.S. patents, he said.</p>
<div class="lb-trans"><p>梅里尔表示，ReposiTrak 在本季度提交了两个额外的专利申请。其中一个与无接触可追溯性直接相关，另一个涵盖了在集成供应链环境中识别和自动纠正数据完整性问题的方法。他表示，公司现在拥有九项美国专利的组合。</p>
</div><p>Fields said a leading grocery retailer and a leading wholesale grocery cooperative in the southern U.S. achieved full end-to-end traceability using ReposiTrak’s Touchless Traceability solution in the last 45 days. He said those customers can track products from suppliers to distribution centers and then to retail stores without touching the product or investing heavily in manual processes.</p>
<div class="lb-trans"><p>Fields 表示，南部美国的一家领先的杂货零售商和一家领先的批发杂货合作社在过去 45 天内使用 ReposiTrak 的无接触追溯解决方案实现了全面的端到端追溯。他表示，这些客户可以在不接触产品或大量投资于手动流程的情况下，从供应商追踪产品到分销中心，再到零售店。</p>
</div><p>Fields also said the accuracy of supplier data remains a major traceability issue. He said the initial error rate in supplier data the company receives is at least 50% and can be as high as 70%, adding that the problem is often incorrect data rather than missing data. He said ReposiTrak has developed an AI-based system to identify and correct such errors in near real time.</p>
<div class="lb-trans"><p>Fields 还表示，供应商数据的准确性仍然是一个主要的追溯问题。他说，公司收到的供应商数据的初始错误率至少为 50%，最高可达 70%，并补充说，问题通常是数据不正确而不是缺失数据。他表示，ReposiTrak 开发了一种基于人工智能的系统，以近实时识别和纠正此类错误。</p>
</div><h2>SPAR collaboration aimed at in-store execution</h2>
<div class="lb-trans"><h2>SPAR 合作旨在店内执行</h2>
</div><p>Fields also discussed ReposiTrak’s collaboration with SPAR Group, saying it could extend the company’s capabilities from identifying supply chain and retail issues to helping resolve them. He said ReposiTrak can identify problems such as out-of-stock situations, products that need to be removed from shelves or recall-related issues, while SPAR can provide teams to address those issues in stores.</p>
<div class="lb-trans"><p>Fields 还讨论了 ReposiTrak 与 SPAR 集团的合作，表示这可以将公司的能力从识别供应链和零售问题扩展到帮助解决这些问题。他表示，ReposiTrak 可以识别诸如缺货、需要从货架上移除的产品或召回相关问题等问题，而 SPAR 可以提供团队来解决这些问题。</p>
</div><p>“The bottleneck in retail isn’t intelligence, it’s hands,” Fields said. “SPAR brings the hands.”</p>
<div class="lb-trans"><p>“零售中的瓶颈不是智能，而是人手，” Fields 说。“SPAR 提供人手。”</p>
</div><p>In response to a question from Maxim Group analyst Thomas Forte, Fields said investors may begin to see the financial impact of the SPAR relationship in six to nine months. He said ReposiTrak and SPAR had already presented the concept to a large consumer products and drug company, and he characterized the potential opportunity as meaningful if it develops.</p>
<div class="lb-trans"><p>在回应 Maxim Group 分析师 Thomas Forte 的问题时，Fields 表示，投资者可能会在六到九个月内开始看到 SPAR 关系的财务影响。他表示，ReposiTrak 和 SPAR 已经向一家大型消费品和制药公司展示了这一概念，并将潜在机会描述为有意义，如果能够发展的话。</p>
</div><p>Looking ahead, Merrill said ReposiTrak’s priorities remain disciplined execution, sustainable recurring revenue growth, profitability expansion, prudent capital allocation, balance sheet strength and long-term shareholder value creation. Fields said the company is seeing “excellent expansion” in its supply chain business and the earliest stages of acceleration in traceability work, while noting that both services have lags between activity and revenue recognition.</p>
<div class="lb-trans"><p>展望未来，Merrill 表示 ReposiTrak 的优先事项仍然是有序执行、可持续的经常性收入增长、盈利能力扩展、审慎的资本配置、资产负债表强度和长期股东价值创造。Fields 表示，公司在供应链业务中看到 “出色的扩展”，并在追溯工作中注意到加速的初始阶段，同时指出这两项服务在活动和收入确认之间存在滞后。</p>
</div><h2>About ReposiTrak NYSE: TRAK</h2>
<div class="lb-trans"><h2>关于 ReposiTrak NYSE: TRAK</h2>
</div><p>ReposiTrak, trading on the New York Stock Exchange under the symbol TRAK, is a provider of cloud-based supply chain compliance and transparency solutions. The company's platform enables retailers, suppliers and manufacturers to manage, share and validate product data throughout the supply chain. Through its Software-as-a-Service (SaaS) offering, ReposiTrak helps organizations ensure adherence to regulatory requirements, industry standards and retailer-specific guidelines for food safety, sustainability, labeling and quality assurance.</p>
<div class="lb-trans"><p>ReposiTrak 在纽约证券交易所以 TRAK 为交易符号，是一家提供基于云的供应链合规性和透明度解决方案的公司。该公司的平台使零售商、供应商和制造商能够在整个供应链中管理、共享和验证产品数据。通过其软件即服务（SaaS）产品，ReposiTrak 帮助组织确保遵守食品安全、可持续性、标签和质量保证的监管要求、行业标准和零售商特定指南。</p>
</div><p>At the core of ReposiTrak's offerings is its DataHub, a centralized repository that captures critical information such as product specifications, certifications, catch-weight data, temperature logs and recall notifications.</p>
<div class="lb-trans"><p>ReposiTrak 产品的核心是其 DataHub，这是一个集中存储库，捕获关键的信息，如产品规格、认证、称重数据、温度记录和召回通知。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ReposiTrak Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 ReposiTrak 吗？</h2>
</div><p>Before you consider ReposiTrak, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 ReposiTrak 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReposiTrak wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买...而 ReposiTrak 并不在名单上。</p>
</div><p>While ReposiTrak currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ReposiTrak 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ReposiTrak 第三季度财报电话会议亮点